{{Drugbox
| verifiedrevid = 447908524
| IUPAC_name = Glucurono-2-amino-2-deoxyglucoglucan sulfate

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|sulodexide}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| routes_of_administration = Oral, Subcutaneous, Intravenous, Intramuscular

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 57821-29-1
| ATC_prefix = B01
| ATC_suffix = AB11
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB06271
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08547

<!--Chemical data-->
}}
'''Sulodexide''' is a highly purified mixture of [[glycosaminoglycans]] composed of [[low molecular weight heparin]] (80%) and [[dermatan sulfate]] (20%).

==Pharmacology==
The low molecular weight of both sulodexide fractions allows for extensive oral absorption compared to unfractionated [[heparin]].  The pharmacological effects of sulodexide differ substantially from other glycosaminoglycans and are mainly characterized by a prolonged half-life and reduced effect on global coagulation and bleeding parameters.<ref>{{Cite journal|vauthors=Lauver DA, Lucchesi BR |title=Sulodexide: a renewed interest in this glycosaminoglycan |journal=Cardio drug rev |volume=24 |issue=3-4 |pages=214–26 |year=2006 |pmid=17214598 |doi=10.1111/j.1527-3466.2006.00214.x}}</ref>  Due to the presence of both glycosaminoglycan fractions, sulodexide potentiates the antiprotease activities of both [[antithrombin III]] and [[heparin cofactor II]] simultaneously.<ref>{{Cite journal|author=Harenberg J |title=Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide |journal=Med Res Rev |volume=18 |issue=1 |pages=1–20 |year=1998 |pmid=9436179 |doi=10.1002/(SICI)1098-1128(199801)18:1<1::AID-MED1>3.0.CO;2-4}}</ref>

==Uses==
Clinically, sulodexide is used for the prophylaxis and treatment of thromboembolic diseases however recent research has also demonstrated the beneficial effects of sulodexide in animal models of [[reperfusion injury]]<ref>{{Cite journal|vauthors=Lauver DA, Booth EA, White AJ, Poradosu E, Lucchesi BR | title = Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis | journal = J Pharmacol Exp Ther | year=2005 | volume=312 | issue=2 |pages=794–800 | pmid = 15365091 | doi = 10.1124/jpet.104.075283}}</ref> and the treatment of [[diabetic nephropathy]].<ref>{{Cite journal|vauthors=Achour A, Kacem M, Dibej K, Skhiri H, Bouraoui S, El May M | title = One year course of oral sulodexide in the management of diabetic nephropathy | journal = J Nephrol | year=2005 | volume=18 | pages=568–574 | pmid = 16299683 | issue = 5 }}</ref><ref>{{Cite journal |vauthors=Gambaro G, Venturini AP, Noonan DM, etal | title = Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy | journal = Kidney Int | year=1994 | volume=46 | pages=797–806 | pmid = 7527876 | doi = 10.1038/ki.1994.335 | issue = 3 }}</ref><ref>{{Cite journal| vauthors = Škrha J, Perušičová J, Pont'uch P, Okša A| title = Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy | journal = Diabetes Res Clin Practice | year=1997 | volume=38 | pages=25–31 | pmid = 9347243 | doi = 10.1016/S0168-8227(97)00076-4 | url = http://www.sciencedirect.com/science/article/pii/S0168822797000764 | issue = 1 |display-authors=etal}}</ref>
In combination with [[Melatonin]], Sulodexide have been shown to be a viable treatment option for patients suffering from central or sensorineural tinnitus.<ref>{{Cite journal |vauthors=Neri G, Baffa C, De Stefano A, etal |title=Management of tinnitus: oral treatment with melatonin and sulodexide |journal=J. Biol. Regul. Homeost. Agents |volume=23 |issue=2 |pages=103–10 |year=2009 |pmid=19589291 }}</ref><ref>Neri G.  De Stefano A.  Baffa C.  Kulamarva G.  Di Giovanni P.  Petrucci G.  Poliandri A.  Dispenza F.  Citraro L.  Croce A. ,"Treatment of central and sensorineural tinnitus with orally administered Melatonin and Sulodexide: personal experience from a randomized controlled study." ''Acta Otorhinolaryngologica Italica.''  29(2):86-91, 2009 Apr.</ref>

==References==
{{Reflist}}

==External links==
* {{MeshName|sulodexide}}

{{Antithrombotics}}

[[Category:Glycosaminoglycans]]


{{Blood-drug-stub}}